Randomized trial of l-serine in patients with hereditary sensory and autonomic neuropathy type 1.


Journal

Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060

Informations de publication

Date de publication:
22 01 2019
Historique:
received: 15 03 2018
accepted: 28 09 2018
pubmed: 11 1 2019
medline: 18 10 2019
entrez: 11 1 2019
Statut: ppublish

Résumé

To evaluate the safety and efficacy of l-serine in humans with hereditary sensory autonomic neuropathy type I (HSAN1). In this randomized, placebo-controlled, parallel-group trial with open-label extension, patients aged 18-70 years with symptomatic HSAN1 were randomized to l-serine (400 mg/kg/day) or placebo for 1 year. All participants received l-serine during the second year. The primary outcome measure was the Charcot-Marie-Tooth Neuropathy Score version 2 (CMTNS). Secondary outcomes included plasma sphingolipid levels, epidermal nerve fiber density, electrophysiologic measurements, patient-reported measures, and adverse events. Between August 2013 and April 2014, we enrolled and randomized 18 participants, 16 of whom completed the study. After 1 year, the l-serine group experienced improvement in CMTNS relative to the placebo group (-1.5 units, 95% CI -2.8 to -0.1, High-dose oral l-serine supplementation appears safe in patients with HSAN1 and is potentially effective at slowing disease progression. NCT01733407. This study provides Class I evidence that high-dose oral l-serine supplementation significantly slows disease progression in patients with HSAN1.

Identifiants

pubmed: 30626650
pii: WNL.0000000000006811
doi: 10.1212/WNL.0000000000006811
pmc: PMC6345118
doi:

Substances chimiques

1-deoxysphingolipid 0
Sphingolipids 0
UCHL1 protein, human 0
Serine 452VLY9402
SPTLC1 protein, human EC 2.3.1.50
Serine C-Palmitoyltransferase EC 2.3.1.50
Ubiquitin Thiolesterase EC 3.4.19.12

Banques de données

ClinicalTrials.gov
['NCT01733407']

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

e359-e370

Subventions

Organisme : NINDS NIH HHS
ID : K24 NS059892
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS072446
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS082331
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS093653
Pays : United States

Informations de copyright

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

Références

BMJ Open Diabetes Res Care. 2015 Mar 19;3(1):e000073
pubmed: 25815206
Neurology. 2009 Jan 13;72(2):177-84
pubmed: 19056667
Biochim Biophys Acta. 2004 Mar 2;1688(2):168-75
pubmed: 14990347
FASEB J. 2015 Nov;29(11):4461-72
pubmed: 26198449
J Neurol Sci. 2005 Jan 15;228(1):65-9
pubmed: 15607212
J Biol Chem. 2009 Feb 20;284(8):4786-95
pubmed: 19095642
Neurology. 2008 Jan 29;70(5):378-83
pubmed: 18227419
PLoS One. 2017 Jun 5;12(6):e0179313
pubmed: 28582468
Hum Mol Genet. 2016 Mar 1;25(5):853-65
pubmed: 26681808
JAMA Neurol. 2013 Aug;70(8):981-7
pubmed: 23797954
Diabetologia. 2012 Feb;55(2):421-31
pubmed: 22124606
Brain. 2006 Feb;129(Pt 2):411-25
pubmed: 16364956
Lancet Neurol. 2016 Jan;15(1):65-77
pubmed: 26549782
Mayo Clin Proc. 1993 Aug;68(8):748-52
pubmed: 8392653
J Clin Invest. 2011 Dec;121(12):4735-45
pubmed: 22045570
Eur J Neurol. 2015 May;22(5):806-14, e55
pubmed: 25623782
Neuroscience. 2011 Feb 3;174:190-9
pubmed: 21118710
J Biol Chem. 2010 Apr 9;285(15):11178-87
pubmed: 20097765
Brain. 2009 Dec;132(Pt 12):3252-62
pubmed: 19843647
Diabetes. 2014 Apr;63(4):1326-39
pubmed: 24379346
Hum Mol Genet. 2005 Nov 15;14(22):3507-21
pubmed: 16210380
Nat Genet. 2001 Mar;27(3):261-2
pubmed: 11242106
Nat Genet. 2001 Mar;27(3):309-12
pubmed: 11242114
Diabetes. 2015 Mar;64(3):1035-45
pubmed: 25277395
Muscle Nerve. 2015 Apr;51(4):489-95
pubmed: 25042817
J Neurosci. 2009 Nov 18;29(46):14646-51
pubmed: 19923297
Neuromolecular Med. 2017 Mar;19(1):46-56
pubmed: 27388466
J Inherit Metab Dis. 2006 Apr-Jun;29(2-3):347-51
pubmed: 16763900
J Neurosci. 2015 Oct 7;35(40):13713-9
pubmed: 26446223

Auteurs

Vera Fridman (V)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Saranya Suriyanarayanan (S)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Peter Novak (P)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

William David (W)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Eric A Macklin (EA)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Diane McKenna-Yasek (D)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Kailey Walsh (K)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Razina Aziz-Bose (R)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Anne Louise Oaklander (AL)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Robert Brown (R)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Thorsten Hornemann (T)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester.

Florian Eichler (F)

From the Department of Neurology (V.F., W.D., K.W., R.A.-B., A.L.O., F.E.), Biostatistics Center, Department of Medicine (E.A.M.), and Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Harvard Medical School, Boston; Clinical Chemistry (S.S., T.H.), University Hospital Zurich, Switzerland; and University of Massachusetts Medical School (P.N., D.M.-Y., R.B.), Worcester. feichler@partners.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH